Newsroom

Sorted by: Latest

-

Xtrackers UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Xtrackers Investment company with variable capital (Société d'investissement à capital variable) Registered office: 49, avenue J.F. Kennedy, L-1855 Luxembourg R.C.S. Luxembourg B-119.899 (the “Company”) NOTICE TO SHAREHOLDERS OF THE SUB-FUNDS LISTED ON THE LONDON STOCK EXCHANGE Luxembourg, 22 July 2026 The board of directors of the Company (the “Board of Directors”) hereby informs all shareholders of the sub-funds listed in the table below (each a “Sub-Fund”, and toge...
-

BRCB Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Black Rock Coffee Bar Securities Lawsuit - Contact Levi & Korsinsky

NEW YORK--(BUSINESS WIRE)--Institutional investors holding positions in Black Rock Coffee Bar, Inc. (NASDAQ: BRCB) during the period September 12, 2025 through May 12, 2026 may wish to evaluate lead plaintiff opportunities in a pending securities class action. Request an institutional investor loss assessment. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500. BRCB shares declined $3.32 per share, or 30.3%, on May 13, 2026, following corrective disclosures a...
-

Enveda’s Positive Phase 1B Results for ENV-294, a Potential First-in-Class Oral Therapy for Moderate-to-Severe Atopic Dermatitis, Were Presented at AAD Innovation Academy; Additional Details to Be Shared at EADV

BOULDER, Colo.--(BUSINESS WIRE)--Enveda, a clinical-stage biotech company developing first-in-class small molecules derived from life’s chemistry, had results from its Phase 1b atopic dermatitis trial presented in New York at last week’s 2026 American Academy of Dermatology (AAD) Innovation Academy, and announced its acceptance for an oral presentation at the European Academy of Dermatology and Venereology (EADV) Congress 2026 in Vienna. “Patients want oral therapies; the problem is with our cu...
-

REGN Shareholder Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky

NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky, LLP alerts investors in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) that a securities class action has been filed on behalf of shareholders who purchased securities between August 1, 2025 and May 15, 2026. Find out if you might be eligible to recover losses. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500. REGN traded as high as $731.77 on April 28, 2026 and closed at $629.68 after the Company announced t...
-

Assent lance l'Integration Connector, une solution qui assure la conformité et l'automatisation des données de durabilité dans l'ensemble de l'entreprise

OTTAWA, Ontario--(BUSINESS WIRE)--Assent Inc. (Assent), le principal réseau d'intelligence des produits au service de l'industrie manufacturière, présente aujourd'hui l'Assent Integration Connector. Cette nouvelle capacité connecte directement les systèmes d'entreprise (ERP, PLM, EHS et plateformes de chaîne d'approvisionnement) à Assent. Les données de conformité et de durabilité sont désormais mises à jour automatiquement au fur et à mesure des changements, et ne reposent plus sur des exporta...
-

AM Best Revises Outlooks to Stable for Qatar General Insurance & Reinsurance Company QPSC

LONDON--(BUSINESS WIRE)--AM Best has revised the outlooks to stable from negative and affirmed the Financial Strength Rating of B++ (Good) and the Long-Term Issuer Credit Rating of “bbb” (Good) of Qatar General Insurance & Reinsurance Company QPSC (QGIRC) (Qatar).These Credit Ratings (ratings) reflect QGIRC’s consolidated balance sheet strength, which AM Best assesses as very strong, as well as its adequate operating performance, limited business profile and appropriate enterprise risk manag...
-

NovoMed PARTNERS Officially Launches to Build the Next Generation of Transformative Medical Technology Companies

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--NovoMed PARTNERS, a new healthcare innovation and growth platform founded by a team of trusted medtech entrepreneurs and executive operators, today officially launched its operations.Founded by Ramin Mousavi, former CEO of CathWorks, and an accomplished group of co-founders, Mike Feher, Fabian Ngo, and Natalie Sickler, NovoMed PARTNERS brings together an executive leadership team with decades of experience building category-defining medical technology comp...
-

Moniepoint publie son premier rapport d'impact, révélant comment le tout premier accès au crédit transforme les entreprises africaines

LAGOS, Nigeria--(BUSINESS WIRE)--Moniepoint Inc. (« Moniepoint » ou la « Société »), plateforme africaine d'écosystème financier tout-en-un pour les particuliers, les entreprises et leurs clients, publie aujourd'hui son premier rapport d'impact intitulé « Créer le bonheur financier ». Ce rapport retrace l’évolution de Moniepoint, passé d’un fournisseur d’infrastructures financières à un écosystème financier complet, et aujourd’hui su service de plus de 20 millions d’entreprises et de particulie...
-

Kodama Unveils Hand-Signed Baki The Grappler Premium Art Edition at Comic-Con® 2026

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kodama Tales Inc. today unveiled its first premium manga art edition: a limited run of twelve hand-signed Baki The Grappler works by Keisuke Itagaki, produced in Japan through Kyodo Printing's Saibiban fine-art process, then finished and framed by hand. Arriving for the series’ 35th anniversary, the edition will premiere at Comic-Con® 2026 in San Diego. Each piece carries Itagaki’s own signature and thumbprint. The debut work captures Baki’s raw presence:...
-

Susan G. Komen® to Deliver Urgent Message at Second Annual October Party in Pink Event: “Ending Deaths from Breast Cancer is Within Our Grasp; Together We Will Make it Happen”

NEW YORK--(BUSINESS WIRE)--Susan G. Komen®, the world’s leading breast cancer organization, is doubling down on its mission “to end deaths from breast cancer” and rallying supporters at its second annual Party in Pink in NYC on October 14th. The event is Komen’s largest opportunity for corporate leaders and philanthropists to commit critical support for people facing breast cancer today and in the future.This year alone, an estimated 321,910 women and 2,670 men in the U.S. will be diagnosed with...